Section 5 of 6
Economic information and modeling report
11 evidence topics · 10 sources
Modeling overview
Summary
No cost-effectiveness or budget impact model of claseprubart has been published. Published analyses in CIDP evaluate efgartigimod alfa and immunoglobulin. CDA-AMC estimated an incremental cost-effectiveness ratio for efgartigimod alfa injection of $1,872,111 per QALY gained compared with immunoglobulin, and recommended reimbursement with conditions, including that its total cost not exceed that of immunoglobulin after the first 6 months. The second NICE draft guidance, open for consultation from 03 November 2026 to 23 November 2026, states that efgartigimod should not be used to treat progressive or relapsing active CIDP in adults after corticosteroids or immunoglobulins, with publication expected on 24 February 2027. A model from a US integrated delivery network perspective projected a total budget impact of $45,996,708, a 35.5% increase, from 10% uptake of efgartigimod alfa in year 1 among an expected 708 immunoglobulin-treated individuals with CIDP in a hypothetical 25-million-member health plan. A Markov model of 5 years of treatment estimated an incremental cost per QALY gained of $687,287 for intravenous immunoglobulin compared with corticosteroids. The company assumes an immunoglobulin price per patient of approximately $150,000 per year and an average biologic net price per patient of approximately $700,000 per year in the US CIDP market.
CDA-AMC reimbursement recommendation for efgartigimod alfa injection in CIDP: cost-effectiveness and budget impact
CDA-AMC economic review of the sponsor's cost-utility model for efgartigimod alfa injection in CIDP
NICE draft guidance on efgartigimod for CIDP (ID6409): recommendation and model structure
NICE appraisal of efgartigimod for CIDP (ID6409): status and schedule
US cost per responder of IVIG versus subcutaneous efgartigimod
“A cost per responder analysis compared Vyvgart hytrulo with Panzyga administered at standard (1 g/kg) and higher (2 g/kg) maintenance doses over 6- and 12-month time horizons.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, costs were $190,026, $402,301, and $698,583, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, cost per responder was $256,792 for Panzyga 1 g/kg, $473,295 for Panzyga 2 g/kg, and $1,455,382 for Vyvgart hytrulo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While no head-to-head clinical trial data were available, differences in trial design and responder definitions between studies may affect comparability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
US budget impact of adding efgartigimod alfa for patients receiving immunoglobulin
Cost-utility of IVIG compared with corticosteroids in Canada
“A markov model was used to evaluate the costs and QALYs for IVIG and corticosteroids over 5 years of treatment for CIDP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incremental cost per QALY gained of IVIG was estimated to be $687,287.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cost per QALY of IVIG was sensitive to the assumptions regarding frequency and dosing of maintenance IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conclusions Based on common willingness to pay thresholds, IVIG would not be perceived as a cost effective treatment for CIDP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-utility of IVIG plus corticosteroids in steroid-resistant CIDP in Thailand
“A Markov model was constructed to estimate the lifetime costs and outcomes for IVIG plus corticosteroids in comparison with immunosuppressants plus corticosteroids in steroid-resistant CIDP patients from a societal perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the base-case, the incremental costs and quality-adjusted life years (QALYs) of IVIG plus corticosteroids versus immunosuppressants plus corticosteroids were US$2112.02 and 1.263 QALYs, respectively, resulting in an incremental cost-effectiveness ratio (ICER) of US$1672.71 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company market assumptions for claseprubart in CIDP
Cost-utility of intravenous immunoglobulin compared with prednisolone in a European crossover trial
“Patients were recruited to a double-blind randomized crossover trial from nine European centres and received either prednisolone or IVIg during the first 6-week treatment period on which the economic evaluation was based.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The main outcome measure in the economic evaluation was the number of quality adjusted life years (QALYs) gained, with change in a 11-point disability scale used to measure clinical outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cost difference between the two treatments was estimated to be euro 3754 over the 6-week period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using a net-benefit approach it was shown that the probability of IVIg being cost-effective in comparison with prednisolone was 0.5 or above (i.e. was more likely to be cost-effective than cost-ineffective) only if one QALY was valued at over euro 250 000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cost-effectiveness of IVIg is greatly affected by the price of IVIg and the amount administered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.